Ally Bridge Group NY LLC Decreases Stake in Context Therapeutics Inc. (NASDAQ:CNTX)

Ally Bridge Group NY LLC cut its holdings in shares of Context Therapeutics Inc. (NASDAQ:CNTX) by 6.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,757,524 shares of the company’s stock after selling 128,708 shares during the period. Context Therapeutics comprises about 1.8% of Ally Bridge Group NY LLC’s investment portfolio, making the stock its 28th biggest holding. Ally Bridge Group NY LLC owned approximately 2.34% of Context Therapeutics worth $3,445,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Renaissance Technologies LLC grew its stake in Context Therapeutics by 63.4% during the 2nd quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock valued at $131,000 after purchasing an additional 25,300 shares in the last quarter. Opaleye Management Inc. boosted its stake in shares of Context Therapeutics by 13.7% during the 1st quarter. Opaleye Management Inc. now owns 1,108,357 shares of the company’s stock valued at $1,530,000 after buying an additional 133,357 shares during the last quarter. Affinity Asset Advisors LLC grew its position in shares of Context Therapeutics by 392.4% during the second quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock worth $3,246,000 after buying an additional 1,290,323 shares in the last quarter. Nantahala Capital Management LLC bought a new stake in shares of Context Therapeutics in the second quarter worth $3,881,000. Finally, Driehaus Capital Management LLC acquired a new stake in Context Therapeutics in the second quarter valued at $4,527,000. 14.03% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CNTX has been the subject of several recent analyst reports. HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of Context Therapeutics in a report on Monday, September 23rd. D. Boral Capital assumed coverage on Context Therapeutics in a research note on Monday. They issued a “buy” rating and a $9.00 price target for the company. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Context Therapeutics has an average rating of “Buy” and a consensus target price of $6.80.

Context Therapeutics Stock Performance

Shares of NASDAQ:CNTX opened at $1.50 on Thursday. Context Therapeutics Inc. has a 1-year low of $0.77 and a 1-year high of $2.75. The company’s fifty day moving average is $1.96 and its two-hundred day moving average is $2.07. The stock has a market capitalization of $112.50 million, a price-to-earnings ratio of -1.65 and a beta of 2.25.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.11). Sell-side analysts expect that Context Therapeutics Inc. will post -0.51 EPS for the current fiscal year.

Context Therapeutics Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.